The settlement resolves allegations that Merck made false statements about the safety of Vioxx and marketed it as a treatment for rheumatoid arthritis before getting approval.
The company agreed to pay a total of $950 million in its agreement with the federal government, forty-three states and the District of Columbia.
Merck says the settlement does not constitute an admission of liability or wrongdoing.
- Drug Maker Merck Resolves Outstanding Vioxx Claims With $950 Million Payment
- Merck to pay nearly $1 billion over Vioxx
- Merck to pay $950 million settlement to conclude Vioxx chapter
- Merck ordered to pay $950M in Vioxx case – CBS News